NIH R01 · 2025
PROJECT SUMMARY Nonalcoholic fatty liver disease (NAFLD) affects 25-30% of US adults and has a major impact on healthcare burden and population health due to higher morbidity and mortality than the general population. Even though NAFLD can progress to cirrhosis, decompensation, and liver cancer, these outcomes affect a small proportion of patients, but there are no accurate methods that are accessible in primary care to identify these patients early. The heterogeneity of clinical phenotypes, lack of universal screening, and risk-stratification approaches lead to delayed diagnosis, phenotype-specific prophylactic or therapeutic intervention, and poor patient outcomes. The long-term goal is…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.